Daré Bioscience Releases Q1 2026 Financial Results

AlphaStreet Newsdesk powered by AlphaStreet Intelligence

DARE|EPS -$0.20 vs -$0.30 est (+33.3%)|Rev $152,455|Net Loss $3.0M

Daré Bioscience, Inc. (DARE) posted a Q1 2026 diluted loss of $0.20 per share, narrower than the -$0.30 expected loss (33.3% narrower). The company generated $152,455 in revenue for the quarter.

Daré Bioscience, Inc. is a Biotechnology company. The company posted a net loss of $3.0M for the quarter.

Wall Street consensus stands at 7 buy, 1 hold, 0 sell. Year-over-year, the per-share loss narrowed to $0.20 from $0.50 in Q1 2025, a 60.0% improvement. Revenue was up 499.6% from $25,427 in Q1 2025.

A detailed analysis of Daré Bioscience, Inc.’s quarter follows shortly on AlphaStreet.

This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.